3 Generic Pharma Exporter Stocks With a Strong Future Roadmap: Strides Pharma Science, Granules India and Marksans Pharma

Generic pharma exporter stocks give investors exposure to Indian makers that supply low-cost medicines to regulated markets abroad. Results depend on product approvals, pricing in export markets and plant compliance, which is why margins and cash flow matter as much as headline growth.

This list covers three US generics stocks: Strides Pharma Science for generic formulations for regulated markets, mainly the United States, Granules India for paracetamol, active ingredients and finished dosage forms and Marksans Pharma for over-the-counter products and generic formulations for the United Kingdom and United States. Every figure comes from the latest reported financials and the 6 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic Pharma Exporter Stocks?

Generic pharma exporter stocks are shares of drug makers that sell generic formulations, over-the-counter products and active ingredients mainly to regulated markets such as the United States and the United Kingdom. Results depend on product approvals, export pricing, plant compliance and operating margin, so a deep product range and clean plants separate the stronger names.

Generic Pharma Exporter Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three generic pharma exporter stocks as of the 6 October 2026 close.

Among US generics stocks, all three trade below their industry P/E multiples.

Why Do Generic Pharma Exporter Stocks Have a Strong Roadmap in India?

Generic pharma exporter stocks have a strong roadmap in India because export markets keep opening to generics, new approvals add products and makers keep expanding capacity. Three drivers stand out.

• Generic demand abroad: Health systems in regulated markets keep switching to lower-cost generics.
• New approvals: Each new approval widens the product range sold abroad.
• Capacity expansion: New plants and lines support higher volumes.

Strides Pharma Science: US Generics and New Approvals Anchor the Roadmap

Strides' roadmap rests on generic formulations for regulated markets, with new product approvals and capacity expansion supporting export growth.

Revenue grew from Rs 3,202.24 crore in FY22 to Rs 5,009.40 crore in FY26, a 56.4% rise, and FY26 revenue was 8.3% higher than FY25. FY26 net profit rose 40.3% to Rs 574.52 crore. In Q1 FY27, revenue grew 12.6% to Rs 1,270.30 crore, and net profit rose 56.7% to Rs 165.49 crore. Operating margin was 21.60% in FY26 and 23.44% in Q1 FY27 against 19.50% a year earlier.

Debt to equity is 0.57 and return on equity is 17.90%. FY26 operating cash flow was Rs 702.52 crore against capital expenditure of Rs 417.94 crore. Strides paid a dividend of Rs 5 per share for FY26, a yield of 0.46%. At a P/E of 15.80 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: Net profit was a loss in FY22, FY23 and FY24, and capex rose to Rs 417.94 Cr in FY26 from Rs 118.15 Cr in FY24.

Granules India: Paracetamol, Ingredients and Capacity Drive the Pipeline

Granules' roadmap rests on paracetamol, active pharmaceutical ingredients and finished dosage forms, with capacity expansion widening its export base.

Revenue grew from Rs 3,782.53 crore in FY22 to Rs 5,385.97 crore in FY26, a 42.4% rise, and FY26 revenue was 19.8% higher than FY25. FY26 net profit rose 18.6% to Rs 595.02 crore. Over four years, net profit rose from Rs 412.76 crore in FY22 to Rs 595.02 crore. In Q1 FY27, revenue grew 20.6% to Rs 1,479.04 crore, and net profit rose 59.8% to Rs 179.96 crore. Operating margin was 22.28% in FY26 and 23.29% in Q1 FY27 against 19.62% a year earlier.

Debt to equity is 0.30 and return on equity is 11.70%. FY26 operating cash flow was Rs 793.25 crore against capital expenditure of Rs 558.21 crore. Granules India paid a dividend of Rs 1.75 per share for FY26, a yield of 0.19%. At a P/E of 34.44 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: ROE of 11.70% is the lowest of the three, and capex of Rs 558.21 Cr absorbed most of FY26 operating cash flow.

Marksans Pharma: Over-the-Counter Products and New Approvals Build the Next Leg

Marksans' roadmap rests on over-the-counter products and generic formulations for the United Kingdom and United States, with new approvals widening its range.

Revenue grew from Rs 1,532.69 crore in FY22 to Rs 3,033.47 crore in FY26, a 97.9% rise, and FY26 revenue was 12.8% higher than FY25. FY26 net profit rose 9.8% to Rs 420.06 crore. Over four years, net profit rose from Rs 186.81 crore in FY22 to Rs 420.06 crore. In Q1 FY27, revenue grew 38.5% to Rs 866.20 crore, and net profit rose 173.9% to Rs 159.41 crore. Operating margin was 23.16% in FY26 and 28.36% in Q1 FY27 against 17.06% a year earlier.

Debt to equity is 0.11 and return on equity is 13.82%. FY26 operating cash flow was Rs 458.13 crore against capital expenditure of Rs 130.53 crore. Marksans Pharma paid a dividend of Rs 0.9 per share for FY26, a yield of 0.28%. At a P/E of 28.20 against an industry P/E of 37.19, the stock trades below its industry multiple.

What to watch: FY26 net profit growth of 9.8% was slower than the 21.5% of FY25, and ROE is 13.82%.

Best Generic Pharma Exporter Stocks in India: Strides vs Granules India vs Marksans Pharma on Key Financials

Among the best generic pharma exporter stocks in India, Marksans Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Strides leads on return on equity and the lowest P/E. The table puts the numbers side by side.

Exporter earnings follow approvals and pricing, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Generic Formulation Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen generic pharma exporter stocks and shortlist generic formulation stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 37.19 for all three here.
2. Track operating margin across several quarters, because input costs can move faster than prices.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these generic pharma exporter stocks

Risks to Consider Before Investing in Generic Pharma Exporter Stocks

• Export pricing: Price pressure in the United States can cut margins.
• Plant compliance: Regulatory findings at a plant can delay supplies.
• Capex: Granules and Strides raised capex sharply in recent years.
• Uneven history: Strides reported losses in FY22, FY23 and FY24.

Download the Univest iOS App or Univest Android App to track Strides, Granules India and Marksans Pharma live.

Final Take: Which Stock Has the Strongest Roadmap?

These three generic formulation stocks cover US generics, paracetamol and active ingredients, and over-the-counter products. Marksans Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Strides leads on return on equity and the lowest P/E.

Across US generics stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the generic formulation stocks to buy discussed here.

FAQs on Generic Pharma Exporter Stocks

Which are the best generic pharma exporter stocks in India with a strong roadmap?

Ans. Strides Pharma Science, Granules India and Marksans Pharma stand out for their roadmaps in generic formulations and active ingredients for export. FY26 revenue growth was 8.3% at Strides, 19.8% at Granules India and 12.8% at Marksans Pharma, and return on equity ranges from 11.70% to 17.90%.

Is Strides Pharma Science a good stock to buy now?

Ans. Strides Pharma Science has a debt to equity ratio of 0.57, a return on equity of 17.90% and a P/E of 15.80 against an industry P/E of 37.19. Export pricing, plant compliance and capex move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Strides, Granules India and Marksans Pharma?

Ans. The P/E ratio is 15.80 for Strides (industry 37.19), 34.44 for Granules India (industry 37.19) and 28.20 for Marksans Pharma (industry 37.19). All three trade below the industry multiple.

Which of these generic pharma exporter stocks has the highest return on equity?

Ans. Strides Pharma Science has the highest return on equity at 17.90%, followed by Marksans Pharma at 13.82% and Granules India at 11.70%.

What are the risks of investing in generic pharma exporter stocks?

Ans. The main risks are export price pressure, plant compliance findings, heavy capex and an uneven profit history. Strides reported losses in FY22, FY23 and FY24, and Granules' ROE is 11.70%.

How did Strides, Granules India and Marksans Pharma perform in Q1 FY27?

Ans. Strides Pharma Science reported revenue of Rs 1,270.30 crore, up 12.6% year on year, and net profit rose 56.7% to Rs 165.49 crore. Granules India reported revenue of Rs 1,479.04 crore, up 20.6% year on year, and net profit rose 59.8% to Rs 179.96 crore. Marksans Pharma reported revenue of Rs 866.20 crore, up 38.5% year on year, and net profit rose 173.9% to Rs 159.41 crore.

Do generic pharma exporter stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.46% for Strides, 0.19% for Granules India and 0.28% for Marksans Pharma, based on dividends declared for FY26.

How can I invest in generic pharma exporter stocks in India?

Ans. You can buy generic pharma exporter stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.